Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 40M | 90.3% |
| Operating expense | 54M | 51.7% |
| Net Income | -15M | 3.9% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 164M | 3.5% |
| Total Liabilities | 131M | 16.2% |
| Total Equity | 33M | 27.9% |
| Shares Outstanding | 228M | 0.1% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -16M | 66.1% |
| Cash from financing | 130,000 | 176.2% |
EPS
Financial Highlights for Vaxart in Q2 '25
Vaxart reported a revenue of 40M, which is a 90.3% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Operating Expenses for this period were 54M, showing a 51.7% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -15M, showing a 3.9% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
Vaxart faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
